EVERSANA and pharmaphorum in conversation: ESMO 2024

Oncology
ESMO 2024 EVERSANA, Ann Marie Robertson, Vanitha Sankaran, Gurdip Daffu, Barry Vucsko

The ESMO congress always disseminates the latest results of cancer research, a vibrant gathering and sharing of the latest data, communicating the next promising steps in oncological scientific development, ever seeking to address unmet patient needs.

So it was that pharmaphorum Web Editor Nicole Raleigh found a quiet spot onsite in Barcelona this year to catch up with experts from EVERSANA and discuss their takeaways from the 2024 conference. Tune in to hear more from: Ann Marie Robertson, Chief Commercial Officer, EVP, EVERSANA COMPLETE Oncology, EVERSANA; Barry Vucsko, Senior Vice President, Client Services and Business Development Leader, EVERSANA INTOUCH; Vanitha Sankaran, VP, Medical Strategy, EVERSANA INTOUCH; and Gurdip Daffu, PhD, VP, Medical Strategy (Oncology), EVERSANA INTOUCH.

From the unique to the specifics of antibody-drug conjugates (ADCs) and advancements in women’s cancers, to the proliferation of AI and where it’s all going, and from diagnostics to excitement and hope at what’s on the cusp and what’s yet to come – the sense of bated breath potential is palpable.

Take a watch of the video below, and don’t forget to catch up with other reporting from ESMO 2024 at the sprawling Fira Gran Via centre in Barcelona, including a discussion with Sven Schaffer, Senior Director of Medical Affairs Europe at Illumina, on how a simple blood draw can transform clinical practice in oncology.